Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 113

1.

Rapid and sensitive detection of Escherichia coli O157:H7 in milk and ground beef using magnetic bead-based immunoassay coupled with tyramide signal amplification.

Aydin M, Herzig GP, Jeong KC, Dunigan S, Shah P, Ahn S.

J Food Prot. 2014 Jan;77(1):100-5. doi: 10.4315/0362-028X.JFP-13-274.

PMID:
24406005
2.

Multiple isolated extramedullary relapse of acute promyelocytic leukemia after allogeneic hematopoietic stem cell transplant: a case report and review of literature.

Kothari S, Herzig G, Slone S, Herzig R.

Springerplus. 2013 Dec;2(1):49. doi: 10.1186/2193-1801-2-49. Epub 2013 Feb 12.

3.

Chimerism and tolerance without GVHD or engraftment syndrome in HLA-mismatched combined kidney and hematopoietic stem cell transplantation.

Leventhal J, Abecassis M, Miller J, Gallon L, Ravindra K, Tollerud DJ, King B, Elliott MJ, Herzig G, Herzig R, Ildstad ST.

Sci Transl Med. 2012 Mar 7;4(124):124ra28. doi: 10.1126/scitranslmed.3003509.

4.

High-dose melphalan and the development of hematopoietic stem-cell transplantation: 25 years later.

Lazarus HM, Phillips GL, Herzig RH, Hurd DD, Wolff SN, Herzig GP.

J Clin Oncol. 2008 May 10;26(14):2240-3. doi: 10.1200/JCO.2007.14.7827. No abstract available.

PMID:
18467711
5.

Selective inhibitors of vitamin D metabolism--new concepts and perspectives.

Schuster I, Egger H, Herzig G, Reddy GS, Schmid JA, Schüssler M, Vorisek G.

Anticancer Res. 2006 Jul-Aug;26(4A):2653-68. Review.

6.

Positive pregnancy tests in a nongravid, premenopausal woman due to hCG beta-chain production by multiple myeloma.

Slone SP, Ahmed Z, Cole LA, Elin RJ, Martin AW, Herzig RH, Herzig GP, Miller JJ.

Am J Clin Pathol. 2005 Jul;124(1):108-12.

PMID:
15923168
7.

Microtiter plate cellular assay for human steroid sulfatase with fluorescence readout.

Wolff B, Billich A, Brunowsky W, Herzig G, Lindley I, Nussbaumer P, Pursch E, Rabeck C, Winkler G.

Anal Biochem. 2003 Jul 15;318(2):276-84.

PMID:
12814632
8.

Retrospective multivariate analysis of hepatic veno-occlusive disease after blood or marrow transplantation: possible beneficial use of low molecular weight heparin.

Simon M, Hahn T, Ford LA, Anderson B, Swinnich D, Baer MR, Bambach B, Bernstein SH, Bernstein ZP, Czuczman MS, Slack JL, Wetzler M, Herzig G, Schriber J, McCarthy PL Jr.

Bone Marrow Transplant. 2001 Mar;27(6):627-33.

9.

Selective inhibitors of CYP24: mechanistic tools to explore vitamin D metabolism in human keratinocytes.

Schuster I, Egger H, Astecker N, Herzig G, Schüssler M, Vorisek G.

Steroids. 2001 Mar-May;66(3-5):451-62.

PMID:
11179754
10.

Selective inhibition of vitamin D hydroxylases in human keratinocytes.

Schuster I, Egger H, Bikle D, Herzig G, Reddy GS, Stuetz A, Stuetz P, Vorisek G.

Steroids. 2001 Mar-May;66(3-5):409-22.

PMID:
11179750
11.
12.

1alpha,25-Dihydroxy-3-epi-vitamin D3 a physiological metabolite of 1alpha,25-dihydroxyvitamin D3: its production and metabolism in primary human keratinocytes.

Astecker N, Reddy GS, Herzig G, Vorisek G, Schuster I.

Mol Cell Endocrinol. 2000 Dec 22;170(1-2):91-101.

PMID:
11162893
13.

Tissue plasminogen activator (tPA) as therapy for hepatotoxicity following bone marrow transplantation.

Schriber J, Milk B, Shaw D, Christiansen N, Baer M, Slack J, Tezcan H, Wetzler M, Herzig G.

Bone Marrow Transplant. 1999 Dec;24(12):1311-4.

14.

Quality assurance in day surgery: do we do enough for the parents to prevent stress?

Tönz M, Herzig G, Kaiser G.

Eur J Pediatr. 1999 Dec;158(12):984-8.

PMID:
10592075
15.

Protracted results of dose-intensive therapy using cyclophosphamide, carmustine, and continuous infusion etoposide with autologous stem cell support in patients with relapse or refractory Hodgkin's disease: a phase II study from the North American Marrow Transplant Group.

Fleming DR, Wolff SN, Fay JW, Brown RA, Lynch JP, Bolwell BJ, Stevens DA, Goodman SA, Greer JP, Stein RS, Pineiro LA, Collins RH, Goldsmith LJ, Herzig GP, Herzig RH.

Leuk Lymphoma. 1999 Sep;35(1-2):91-8.

PMID:
10512166
16.

Delphi-panel analysis of appropriateness of high-dose therapy and bone marrow transplants in chronic myelogenous leukemia in chronic phase.

Gale RP, Park RE, Dubois RW, Herzig GP, Hocking WG, Horowitz MM, Keating A, Kempin S, Linker CA, Schiffer CA, Wiernik PH, Weisdorf DJ, Rai KR.

Leuk Res. 1999 Sep;23(9):817-26.

PMID:
10475621
17.

Delphi-panel analysis of appropriateness of high-dose therapy and bone marrow transplants in adults with acute myelogenous leukemia in 1st remission.

Gale RP, Park RE, Dubois RW, Herzig GP, Hocking WG, Horowitz MM, Keating A, Kempin S, Linker CA, Schiffer CA, Wiernik PH, Weisdorf DJ, Rai KR.

Leuk Res. 1999 Aug;23(8):709-18.

PMID:
10456668
18.

Endogenous CD8+ T cell expansion during regression of monoclonal EBV-associated posttransplant lymphoproliferative disorder.

Khatri VP, Baiocchi RA, Peng R, Oberkircher AR, Dolce JM, Ward PM, Herzig GP, Caligiuri MA.

J Immunol. 1999 Jul 1;163(1):500-6.

19.

A phase I study of recombinant human soluble interleukin-1 receptor (rhu IL-1R) in patients with relapsed and refractory acute myeloid leukemia.

Bernstein SH, Fay J, Frankel S, Christiansen N, Baer MR, Jacobs C, Blosch C, Hanna R, Herzig G.

Cancer Chemother Pharmacol. 1999;43(2):141-4.

PMID:
9923819
20.

Sequential interleukin-3 and granulocyte-colony stimulating factor prior to and following high-dose etoposide and cyclophosphamide: a phase I/II trial.

Bernstein SH, Fay JP, Christiansen NP, Pinero L, Shah D, Stephan M, Herzig GP.

Clin Cancer Res. 1997 Sep;3(9):1519-26.

21.

Interferon-alpha-associated focal segmental glomerulosclerosis with massive proteinuria in patients with chronic myeloid leukemia following high dose chemotherapy.

Shah M, Jenis EH, Mookerjee BK, Schriber JR, Baer MR, Herzig GP, Wetzler M.

Cancer. 1998 Nov 1;83(9):1938-46. Review.

PMID:
9806652
22.

Delphi-panel analysis of appropriateness of high-dose therapy and bone marrow transplants in adults with acute lymphoblastic leukemia in first remission.

Gale RP, Park RE, Dubois RW, Herzig GP, Hocking WG, Horowitz MM, Keating A, Kempin S, Linker CA, Schiffer CA, Wiernik PH, Weisdorf DJ, Rai KR.

Leuk Res. 1998 Nov;22(11):973-81.

PMID:
9783798
23.

Expression and function of the megakaryocyte growth and development factor receptor in acute myeloid leukemia blasts.

Wetzler M, Bernstein SH, Baumann H, Fries KM, Stewart C, Blumenson L, Baer MR, Herzig GP, Bloomfield CD, Slack JL.

Leuk Lymphoma. 1998 Aug;30(5-6):415-31.

PMID:
9711904
24.

A multicenter study of platelet recovery and utilization in patients after myeloablative therapy and hematopoietic stem cell transplantation.

Bernstein SH, Nademanee AP, Vose JM, Tricot G, Fay JW, Negrin RS, DiPersio J, Rondon G, Champlin R, Barnett MJ, Cornetta K, Herzig GP, Vaughan W, Geils G Jr, Keating A, Messner H, Wolff SN, Miller KB, Linker C, Cairo M, Hellmann S, Ashby M, Stryker S, Nash RA.

Blood. 1998 May 1;91(9):3509-17.

PMID:
9558412
25.

Severe cerebellar swelling and thrombotic thrombocytopenic purpura associated with FK506.

Tezcan H, Zimmer W, Fenstermaker R, Herzig GP, Schriber J.

Bone Marrow Transplant. 1998 Jan;21(1):105-9.

26.

A randomized phase II study of BB-10010: a variant of human macrophage inflammatory protein-1alpha for patients receiving high-dose etoposide and cyclophosphamide for malignant lymphoma and breast cancer.

Bernstein SH, Eaves CJ, Herzig R, Fay J, Lynch J, Phillips GL, Christiansen N, Reece D, Ericson S, Stephan M, Kovalsky M, Hawkins K, Rasmussen H, Devos A, Herzig GP.

Br J Haematol. 1997 Dec;99(4):888-95.

PMID:
9432038
27.

Rearrangement of ALL1 (MLL) in acute myeloid leukemia with normal cytogenetics.

Caligiuri MA, Strout MP, Lawrence D, Arthur DC, Baer MR, Yu F, Knuutila S, Mrózek K, Oberkircher AR, Marcucci G, de la Chapelle A, Elonen E, Block AW, Rao PN, Herzig GP, Powell BL, Ruutu T, Schiffer CA, Bloomfield CD.

Cancer Res. 1998 Jan 1;58(1):55-9.

28.

Long-term survival of patients with acute myeloid leukemia: updated results from two trials evaluating postinduction chemotherapy.

Bloomfield CD, Herzig GP, Peterson BA, Wolff SN.

Cancer. 1997 Dec 1;80(11 Suppl):2186-90.

PMID:
9395032
29.

Expression of c-mpl mRNA, the receptor for thrombopoietin, in acute myeloid leukemia blasts identifies a group of patients with poor response to intensive chemotherapy.

Wetzler M, Baer MR, Bernstein SH, Blumenson L, Stewart C, Barcos M, Mrózek K, Block AW, Herzig GP, Bloomfield CD.

J Clin Oncol. 1997 Jun;15(6):2262-8.

PMID:
9196139
30.

Transplantation-associated thrombotic thrombocytopenic purpura and hemolytic uremic syndrome.

Schriber JR, Herzig GP.

Semin Hematol. 1997 Apr;34(2):126-33. Review. No abstract available.

PMID:
9109214
31.

Introduction: acute leukemia: recent advances.

Bloomfield CD, Herzig GP, Caligiuri MA.

Semin Oncol. 1997 Feb;24(1):1-2. No abstract available.

PMID:
9045295
32.

CD34 progenitor cell subset analyses in normal human bone marrow and marrow harvested after intermediate-dose chemotherapy.

Laughlin MJ, Christiansen NP, Herzig GP, Blumenson L, Bonney D, Stewart CC.

Cytometry. 1996 Dec 15;26(4):235-42.

33.

Granulocyte-macrophage colony-stimulating factor (GM-CSF) priming of high-dose etoposide and cyclophosphamide: a pilot trial.

Bernstein SH, Christiansen NP, Fay JP, Brown R, Herzig R, Frankel S, Blumenson L, Herzig GP.

Exp Hematol. 1996 Oct;24(12):1363-8.

PMID:
8913281
34.

Persistence of the AML1/ETO fusion transcript in patients treated with allogeneic bone marrow transplantation for t(8;21) leukemia.

Jurlander J, Caligiuri MA, Ruutu T, Baer MR, Strout MP, Oberkircher AR, Hoffmann L, Ball ED, Frei-Lahr DA, Christiansen NP, Block AM, Knuutila S, Herzig GP, Bloomfield CD.

Blood. 1996 Sep 15;88(6):2183-91.

PMID:
8822938
35.

High-dose etoposide, cyclophosphamide and total body irradiation with allogeneic bone marrow transplantation for resistant acute myeloid leukemia: a study by the North American Marrow Transplant Group.

Brown RA, Wolff SN, Fay JW, Pineiro L, Collins RH Jr, Lynch JP, Stevens D, Greer J, Herzig RH, Herzig GP.

Leuk Lymphoma. 1996 Jul;22(3-4):271-7.

PMID:
8819076
36.

Dose-intensive chemotherapy with etoposide-cyclophosphamide for advanced breast cancer. North American Marrow Transplant Group.

Herzig RH, Lynch J, Christiansen NP, Fay JW, Davis MP, Herzig GP.

Semin Oncol. 1996 Apr;23(2 Suppl 4):28-32.

PMID:
8600546
37.

Partial tandem duplication of ALL1 as a recurrent molecular defect in acute myeloid leukemia with trisomy 11.

Caligiuri MA, Strout MP, Schichman SA, Mrózek K, Arthur DC, Herzig GP, Baer MR, Schiffer CA, Heinonen K, Knuutila S, Nousiainen T, Ruutu T, Block AW, Schulman P, Pedersen-Bjergaard J, Croce CM, Bloomfield CD.

Cancer Res. 1996 Mar 15;56(6):1418-25.

38.

Biological effects of recombinant human granulocyte colony-stimulating factor in patients with untreated acute myeloid leukemia.

Baer MR, Bernstein SH, Brunetto VL, Heinonen K, Mrózek K, Swann VL, Minderman H, Block AW, Pixley LA, Christiansen NP, Fay JW, Barcos M, Rustum Y, Herzig GP, Bloomfield CD.

Blood. 1996 Feb 15;87(4):1484-94.

PMID:
8608239
39.

American Society for Blood and Marrow Transplantation guidelines for training.

Appelbaum F, Fay J, Herzig G, Kersey J, Parkman R, Petersdorf E, Przepiorka D, Saral R, Shpall E, Wolf J.

Biol Blood Marrow Transplant. 1995 Nov;1(1):56. No abstract available.

PMID:
9118292
40.

Description of an efficient and highly informative method for the evaluation of hematopoietic chimerism following allogeneic bone marrow transplantation.

Oberkircher AR, Strout MP, Herzig GP, Fritz PD, Caligiuri MA.

Bone Marrow Transplant. 1995 Nov;16(5):695-702.

PMID:
8547867
41.
42.

Molecular rearrangement of the ALL-1 gene in acute myeloid leukemia without cytogenetic evidence of 11q23 chromosomal translocations.

Caligiuri MA, Schichman SA, Strout MP, Mrózek K, Baer MR, Frankel SR, Barcos M, Herzig GP, Croce CM, Bloomfield CD.

Cancer Res. 1994 Jan 15;54(2):370-3.

43.

Bone marrow purging with etoposide/methylprednisolone in patients undergoing autologous bone marrow transplantation.

Pineiro L, Fay J, Collins R, Herzig G.

Prog Clin Biol Res. 1994;389:17-21. No abstract available.

PMID:
7700899
44.

High-dose cytarabine, idarubicin, and granulocyte colony-stimulating factor remission induction therapy for previously untreated de novo and secondary adult acute myeloid leukemia.

Baer MR, Christiansen NP, Frankel SR, Brunetto VL, Mrózek K, Bloomfield CD, Herzig GP.

Semin Oncol. 1993 Dec;20(6 Suppl 8):6-12.

PMID:
7507264
45.
46.

High-dose cytosine arabinoside for the treatment of acute myeloid leukemia. Studies of the North American Marrow Transplant Group.

Wolff SN, Brown RA, Fay JW, Herzig GP, Herzig RH, Phillips GL.

Leukemia. 1992 Nov;6 Suppl 4:71-4. Review. No abstract available.

PMID:
1434839
47.

Bone marrow purging in patients with refractory cancer.

Meagher RC, Stevens DA, Herzig GP, Fay JW, Harden EA, Montes VM, Heye MM, Herzig RH.

Prog Clin Biol Res. 1992;377:281-7. No abstract available.

PMID:
1438426
48.

Neurologic complications in allogeneic bone marrow transplant patients receiving cyclosporin.

Reece DE, Frei-Lahr DA, Shepherd JD, Dorovini-Zis K, Gascoyne RD, Graeb DA, Spinelli JJ, Barnett MJ, Klingemann HG, Herzig GP, et al.

Bone Marrow Transplant. 1991 Nov;8(5):393-401.

PMID:
1768975
49.

Intensive chemotherapy with cyclophosphamide, carmustine, and etoposide followed by autologous bone marrow transplantation for relapsed Hodgkin's disease.

Reece DE, Barnett MJ, Connors JM, Fairey RN, Fay JW, Greer JP, Herzig GP, Herzig RH, Klingemann HG, LeMaistre CF, et al.

J Clin Oncol. 1991 Oct;9(10):1871-9. Erratum in: J Clin Oncol 1992 Jan;10(1):170.

PMID:
1919637

Supplemental Content

Loading ...
Support Center